CytoDyn Inc.’s (CYDY) New HIV Treatment Could Bring a Paradigm Shift in HIV Therapy

September 11, 2018 10:47:05
  • PRO 140 requires one dose a week, rather than daily pills
  • Treatment has shown hardly any side-effects in clinical trials, while current HIV therapies may cause mild to severe side-effects
  • CytoDyn’s treatment is simple for patients to administer with hardly any toxicity

Significant advantages of PRO 140, CytoDyn Inc.’s (OTCQB: CYDY) viral-entry inhibitor, over drugs currently used in HIV treatment therapies have been reported, namely showing little if any toxicity or side-effects in treated patients to date, ease of administration (once weekly dosing) and a lack of HIV resistance developing to the treatment. Although there are several promising HIV therapies currently in development or new on the market, from companies such as Gilead Sciences, Inc. (NASDAQ: GILD), GlaxoSmithKline plc (NYSE: GSK), Johnson & Johnson (NYSE: JNJ) and Merck & Co., Inc. (NYSE: MRK), none are weekly self-administered sub-cutaneous injections in phase 3 development.

Patients on current leading therapies often struggle with treatment compliance due to the complexity of treatment regimens and sometimes high number of pills they must take every day. Non-adherence to current therapies can have…

Read More>>

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office